BRAIN Biotech AG reported earnings results for the third quarter and nine months ended June 30, 2022. For the third quarter, the company reported sales was EUR 12.71 million compared to EUR 9.84 million a year ago. Revenue was EUR 12.98 million compared to EUR 10.17 million a year ago. Net loss was EUR 2.62 million compared to EUR 2.03 million a year ago. Basic loss per share from continuing operations was EUR 0.12 compared to EUR 0.1 a year ago. Diluted loss per share from continuing operations was EUR 0.12 compared to EUR 0.1 a year ago.
For the nine months, sales was EUR 35.97 million compared to EUR 27.85 million a year ago. Revenue was EUR 37.19 million compared to EUR 29.97 million a year ago. Net loss was EUR 6.57 million compared to EUR 3.32 million a year ago. Basic loss per share from continuing operations was EUR 0.3 compared to EUR 0.17 a year ago. Diluted loss per share from continuing operations was EUR 0.3 compared to EUR 0.17 a year ago.